All In Biotech

Drug Trial Radar · NCT05497843

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

An Open-label, Multicenter, Phase II Study of Chiauranib Capsule in Patients With Advanced or Unresectable Soft Tissue Sarcoma Previously Failed to Standard of Care Treatment

Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Aug 25, 2022

Primary completion

Jan 3, 2025

Study completion Jan 3, 2025

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Aug 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.

Conditions

  • Soft Tissue Sarcoma

Interventions

  • ChiauranibDrug

    50mg, orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival of 12 weeks(PFS12w)Time frame: 12 weeks after the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.